Personalized radiation aims to outsmart tough pancreatic tumors
NCT ID NCT06984562
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests whether adaptive radiation therapy (ART) can safely deliver higher, more focused radiation doses to pancreatic tumors while protecting nearby organs. Sixteen adults with locally advanced, inoperable pancreatic cancer will receive five treatments over two weeks. The main goal is to check for serious side effects, with secondary goals of seeing if the tumor stays controlled and how long patients live.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Adaptive Radiation Therapy (ART)
What this could lead to
If successful, this approach could make radiation therapy safer and more effective for people with inoperable pancreatic cancer, potentially improving local tumor control and quality of life.
What could go wrong
This is a very early, small Phase I trial with only 16 participants. It primarily tests safety and dosing, not effectiveness. The cancer is advanced and hard to treat, so benefits may be limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA (PDA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fox Chase Cancer Center
RECRUITINGPhiladelphia, Pennsylvania, 19111, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••